The programmed cell death protein (PD)-1/PD-ligand (PD-L1) axis has recently emerged as a central immune checkpoint that controls antitumor immune responses against both solid tumours and hematologic malignancies. This evidence concerns the gene PDCD1 and hematologic disorder.